Mckesson Corp

Chart & Performance

D1W1MN

P/E

24.39

P/S

0.24

EPS

23.65

Div Yield, %

0.43%

Shrs. gr., 5y

-7.43%

Rev. gr., 5y

7.59%

Revenues

308.95b

+11.65%

Net income

3.00b

-15.67%

CFO

4.31b

-16.38%

Dividend

Aug 30, 20240.71 USD/sh

Earnings

Feb 05, 2025

Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

URL

https://www.mckesson.com/

IPO date

Nov 10, 1994

Employees

45,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	308,951,000 11.65%	276,711,000 4.83%	263,966,000 10.80%
Cost of revenue	304,556,000	272,218,000	261,443,000
Unusual Expense (Income)
NOPBT	4,395,000	4,493,000	2,523,000
NOPBT Margin	1.42%	1.62%	0.96%
Operating Taxes	629,000	905,000	636,000
Tax Rate	14.31%	20.14%	25.21%
NOPAT	3,766,000	3,588,000	1,887,000
Net income	3,002,000 -15.67%	3,560,000 219.57%	1,114,000 -125.67%
Dividends	(314,000)	(292,000)	(277,000)
Dividend yield	0.44%	0.58%	0.59%
Proceeds from repurchase of equity	(2,909,000)	(3,475,000)	(3,296,000)
BB yield	4.04%	6.86%	6.99%
Debt
Debt current	640,000	1,566,000	1,096,000
Long-term debt	8,643,000	7,556,000	8,109,000
Deferred revenue	163,000
Other long-term liabilities	8,886,000	8,611,000	8,760,000
Net debt	4,352,000	4,132,000	5,327,000
Cash flow
Cash from operating activities	4,314,000	5,159,000	4,434,000
CAPEX	(431,000)	(558,000)	(535,000)
Cash from investing activities	(1,072,000)	(542,000)	(89,000)
Cash from financing activities	(3,342,000)	(4,368,000)	(6,321,000)
FCF	5,181,000	4,376,000	4,067,000
Balance
Cash	4,583,000	4,678,000	3,532,000
Long term investments	348,000	312,000	346,000
Excess cash
Stockholders' equity	14,472,000	11,760,000	7,978,000
Invested Capital	14,809,000	14,542,000	14,510,000
ROIC	25.66%	24.70%	10.74%
ROCE	27.95%	28.21%	15.84%
EV
Common stock shares outstanding	134,100	142,200	154,100
Price	536.85 50.78%	356.05 16.31%	306.13 56.96%
Market cap	71,991,585 42.19%	50,630,310 7.33%	47,174,633 50.60%
EV	76,715,585	55,129,310	52,981,633
EBITDA	5,030,000	5,101,000	3,283,000
EV/EBITDA	15.25	10.81	16.14
Interest	252,000	248,000	178,000
Interest/NOPBT	5.73%	5.52%	7.06%